Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Chardan Capital Markets Upgrades Sage Therapeutics (SAGE) to BuyNovember 10, 2017 8:16 AM Sage Therapeutics (SAGE) PT Raised to $135 at CowenNovember 9, 2017 3:20 PM Sage Therapeutics (SAGE) PT Raised to $105 at StifelNovember 9, 2017 12:43 PM Sage Therapeutics (SAGE) PT Raised to $123 at Leerink PartnersNovember 9, 2017 12:13 PM Sage Therapeutics (SAGE) PT Raised to $100 at Needham & CompanyNovember 9, 2017 11:34 AM Sage Therapeutics (SAGE) Hits 'Very Significant Milestone' - BMONovember 9, 2017 10:12 AM SAGE Therapeutics (SAGE) Climbs 50% After Phase 3 Study to Treat Postpartum Depression Meets Primary EndpointNovember 9, 2017 6:42 AM Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum DepressionNovember 9, 2017 6:00 AM